CA
CTNM

Clearstead Advisors’s Contineum Therapeutics CTNM Stock Holding History

Clearstead Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33
Closed -$132 – 3276
2025
Q2 		$132 Buy
+33
New +$143 ﹤0.01% 2589

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Clearstead Advisors's CTNM Position: Q3 2025 in Review

Clearstead Advisors sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 33 shares — an estimated $132 sold.

Clearstead Advisors first reported a position in CTNM in Q2 2025 and held it in 1 quarter. The position peaked at $132 in Q2 2025. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Clearstead Advisors reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 33 Contineum Therapeutics shares in Q3 2025, an estimated $132.
  • Clearstead Advisors first reported a position in Contineum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's Contineum Therapeutics position peaked at $132 in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.